Minocycline inhibits alkali burn-induced corneal neovascularization in mice

PLoS ONE

Volumn 7, Issue 7, 2012, Pages

  Xiao, Ou ^a   Xie, Zhao lian ^a   Lin, Bin wu ^a   Yin, Xiao fang ^a   Pi, Rong biao ^a   Zhou, Shi you ^a  

^a SUN YAT SEN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

COLLAGENASE 3; FIBROBLAST GROWTH FACTOR 2; GELATINASE A; GELATINASE B; INTERLEUKIN 1BETA; INTERLEUKIN 6; MESSENGER RNA; MINOCYCLINE; PHOSPHATE BUFFERED SALINE; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ARTICLE; BASIC FIBROBLAST GROWTH FACTOR GENE; CAUSTIC BURN; CONTROLLED STUDY; CORNEA EPITHELIUM; CORNEA NEOVASCULARIZATION; DOSE RESPONSE; DRUG MEGADOSE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE; GENE EXPRESSION; HISTOPATHOLOGY; INTERLEUKIN 1BETA GENE; LOW DRUG DOSE; MATRIX METALLOPROTEINASE 13 GENE; MATRIX METALLOPROTEINASE 2 GENE; MATRIX METALLOPROTEINASE 9 GENE; MOUSE; NEUTROPHIL CHEMOTAXIS; NONHUMAN; PROTEIN ANALYSIS; PROTEIN EXPRESSION; VASCULOTROPIN RECEPTOR 1 GENE; VASCULOTROPIN RECEPTOR 2 GENE; WOUND HEALING; ZYMOGRAPHY;

ANIMALS; BURNS, CHEMICAL; CORNEAL NEOVASCULARIZATION; EPITHELIUM, CORNEAL; EYE BURNS; FEMALE; HYDROGEN-ION CONCENTRATION; MICE; MICE, INBRED BALB C; MINOCYCLINE; NEUTROPHIL INFILTRATION; RECOVERY OF FUNCTION;

MUS;

EID: 84864352003     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0041858     Document Type: Article

References (49)

1. Wagoner MD, (1997) Chemical injuries of the eye: current concepts in pathophysiology and therapy. Surv Ophthalmol 41: 275-313.
2. Bashshur ZF, Bazarbachi A, Schakal A, Haddad ZA, El Haibi CP, et al. (2006) Intravitreal bevacizumab for the management of choroidal neovascularization in age-related macular degeneration. Am J Ophthalmol 142: 1-9.
3. Li T, Hu A, Li S, Luo Y, Huang J, et al. (2011) KH906, a recombinant human VEGF receptor fusion protein, is a new effective topical treatment for corneal neovascularization. Mol Vis 17: 797-803.
4. Dana MR, Zhu SN, Yamada J, (1998) Topical modulation of interleukin-1 activity in corneal neovascularization. Cornea 17: 403-409.
5. Ellenberg D, Azar DT, Hallak JA, Tobaigy F, Han KY, et al. (2010) Novel aspects of corneal angiogenic and lymphangiogenic privilege. Prog Retin Eye Res 29: 208-248.
6. Federici TJ, (2011) The non-antibiotic properties of tetracyclines: Clinical potential in ophthalmic disease. Pharmacol Res 64: 614-623.
7. Liang D, Yan SL, Lin ML, Li YP, Ma HJ, et al. (2008) Inhibitory effect of oral doxycycline on neovascularization in a rat corneal alkali burn model of angiogenesis. Curr Eye Res 33: 653-660.
8. De Paiva CS, Corrales RM, Villarreal AL, Farley WJ, Li DQ, et al. (2006) Corticosteroid and doxycycline suppress MMP-9 and inflammatory cytokine expression, MAPK activation in the corneal epithelium in experimental dry eye. Exp Eye Res 83: 526-535.
9. Su WR, Li ZR, Lin ML, Li YP, He ZX, et al. (2011) The effect of doxycycline temperature-sensitive hydrogel on inhibiting the corneal neovascularization induced by BFGF in rats. Graef Arch Clin Exp 249: 421-427.
10. Zhu S, Stavrovskaya IG, Drozda M, Kim BY, Ona V, et al. (2002) Minocycline inhibits cytochrome c release and delays progression of amyotrophic lateral sclerosis in mice. Nature 417: 74-78.
11. Brundula V, Rewcastle NB, Metz LM, Bernard CC, Yong VW, (2002) Targeting leukocyte MMPs and transmigration- Minocycline as a potential therapy for multiple sclerosis. Brain 125: 1297-1308.
12. Peyman GA, Kazi AA, Riazi-Esfahani M, Aydin E, Kivilcim M, et al. (2006) The effect of combinations of flurbiprofen, low molecular weight heparin, and doxycycline on the inhibition of corneal neovascularization. Cornea 25: 582-585.
13. Tamargo RJ, Bok RA, Brem H, (1991) Angiogenesis inhibition by minocycline. Cancer Res 51: 672-675.
14. Yao JS, Shen F, Young WL, Yang GY, (2007) Comparison of doxycycline and minocycline in the inhibition of VEGF-induced smooth muscle cell migration. Neurochem Int 50: 524-530.
15. Colovic M, Caccia S, (2003) Liquid chromatographic determination of minocycline in brain-to-plasma distribution studies in the rat. J Chromatogr B Analyt Technol Biomed Life Sci 791: 337-343.
16. Zabad RK, Metz LM, Todoruk TR, Zhang Y, Mitchel JR, et al. (2007) The clinical response to minocycline in multiple sclerosis is accompanied by beneficial immune changes: a pilot study. Mult Scler 13: 517-526.
17. Hawryluk GWJ, Rowland J, Kwon BK, Fehlings MG, (2008) Protection and repair of the injured spinal cord: a review of completed, ongoing, and planned clinical trials for acute spinal cord injury. Neurosurgical Focus 25: E14.
18. Gordon PH, Moore DH, Miller RG, Florence JM, Verheijde JL, et al. (2007) Efficacy of minocycline in patients with amyotrophic lateral sclerosis: a phase III randomised trial. Lancet Neurol 6: 1045-1053.
19. Lahousen T, Bonelli RM, (2003) Neuroprotection in Hungtington's disease. Clin Neuropharmacol 26: 223-224.
20. Kieburtz K, Tilley B, Ravina B, Galpern W, Shannon K, et al. (2008) A pilot clinical trial of creatine and minocycline in early Parkinson disease: 18-month results. Clin Neuropharmacol 31: 141-150.
21. Kim HS, Suh YH, (2009) Minocycline and neurodegenerative diseases. Behav Brain Res 196: 168-179.
22. Zhou SY, Xie ZL, Xiao O, Yang XR, Heng BC, et al. (2010) Inhibition of mouse alkali burn induced-corneal neovascularization by recombinant adenovirus encoding human vasohibin-1. Mol Vis 16: 1389-1398.
23. Blum D, Chtarto A, Tenenbaum L, Brotchi J, Levivier M, (2004) Clinical potential of minocycline for neurodegenerative disorders. Neurobiol Dis 17: 359-366.
24. Proia AD, Chandler DB, Haynes WL, Smith CF, Suvarnamani C, et al. (1988) Quantitation of corneal neovascularization using computerized image analysis. Lab Invest 58: 473-479.
25. Carter RT, Kambampati R, Murphy CJ, Bentley E, (2007) Expression of matrix metalloproteinase 2 and 9 in experimentally wounded canine corneas and spontaneous chronic corneal epithelial defects. Cornea 26: 1213-1219.
26. Jonas M, Cunha BA, (1982) Minocycline. Ther Drug Monit 4: 137-145.
27. Roskoski R Jr, (2008) VEGF receptor protein-tyrosine kinases: structure and regulation. BiochemBiophys Res Commun 375: 287-291.
28. Cao R, Eriksson A, Kubo H, Alitalo K, Cao Y, et al. (2004) Comparative evaluation of FGF-2-, VEGF-A-, and VEGF-C-induced angiogenesis, lymphangiogenesis, vascular fenestrations, and permeability. Circ Res 94: 664-670.
29. Imanishi J, Kamiyama K, Iguchi I, Kita M, Sotozono C, et al. (2000) Growth factors: importance in wound healing and maintenance of transparency of the cornea. Prog Retin Eye Res 19: 113-129.
30. Stapleton WM, Chaurasia SS, Medeiros FW, Mohan RR, Sinha S, et al. (2008) Topical interleukin-1 receptor antagonist inhibits inflammatory cell infiltration into the cornea. Exp Eye Res 86: 753-757.
31. Yamada J, Dana MR, Sotozono C, Kinoshita S, (2003) Local suppression of IL-1 by receptor antagonist in the rat model of corneal alkali injury. Exp Eye Res 76: 161-167.
32. Pabreja K, Dua K, Sharma S, Padi SSV, Kulkarni SK, (2011) Minocycline attenuates the development of diabetic neuropathic pain: Possible anti-inflammatory and anti-oxidant mechanisms. Eur J Pharmacol 661: 15-21.
33. Chen M, Ona VO, Li MW, Ferrante RJ, Fink KB, et al. (2000) Minocycline inhibits caspase-1 and caspase-3 expression and delays mortality in a transgenic mouse model of Huntington disease. Nat Med 6: 797-801.
34. Schonbeck U, Mach F, Libby P, (1998) Generation of biologically active IL-1 beta by matrix metalloproteinases: a novel caspase-1-independent pathway of IL-1 beta processing. J Immunol 161: 3340-3346.
35. Perry HD, Kenyon KR, Lamberts DW, Foulks GN, Seedor JA, et al. (1986) Systemic tetracycline hydrochloride as adjunctive therapy in the treatment of persistent epithelial defects. Ophthalmology 93: 1320-1322.
36. Su WR, Li ZR, Li YP, Lin ML, Yao L, et al. (2011) Doxycycline Enhances the Inhibitory Effects of Bevacizumab on Corneal Neovascularization and Prevents Its Side Effects. Invest Ophth Vis Sci 52: 9108-9115.
37. Ma DH, Chen JK, Kim WS, Hao YX, Wu HC, et al. (2001) Expression of matrix metalloproteinases 2 and 9 and tissue inhibitors of metalloproteinase 1 and 2 in inflammation-induced corneal neovascularization. Ophthalmic Res 33: 353-362.
38. Ralph RA, (2000) Tetracyclines and the treatment of corneal stromal ulceration: a review. Cornea 19: 274-277.
39. Mignatti P, Rifkin DB, (1996) Plasminogen activators and matrix metalloproteinases in angiogenesis. Enzyme Protein 49: 117-137.
40. Kato T, Kure T, Chang JH, Gabison EE, Itoh T, et al. (2001) Diminished corneal angiogenesis in gelatinase A-deficient mice. Febs Letters 508: 187-190.
41. Kvanta A, Sarman S, Fagerholm P, Seregard S, Steen B, (2000) Expression of matrix metalloproteinase-2 (MMP-2) and vascular endothelial growth factor (VEGF) in inflammation-associated corneal neovascularization. Exp Eye Res 70: 419-428.
42. Machado LS, Kozak A, Ergul A, Hess DC, Borlongan CV, et al. (2006) Delayed minocycline inhibits ischemia-activated matrix metalloproteinases 2 and 9 after experimental stroke. Bmc Neurosci 7: 56.
43. Masocha W, Rottenberg ME, Kristensson K, (2006) Minocycline impedes African trypanosome invasion of the brain in a murine model. Antimicrob Agents Chemother 50: 1798-1804.
44. Fortier LA, Motta T, Greenwald RA, Divers TJ, Mayr KG, (2010) Synoviocytes are more sensitive than cartilage to the effects of minocycline and doxycycline on IL-1alpha and MMP-13-induced catabolic gene responses. J Orthop Res 28: 522-528.
45. Gabler WL, Creamer HR, (1991) Suppression of human neutrophil functions by tetracyclines. J Periodontal Res 26: 52-58.
46. Takeshita S, Ono Y, Kozuma K, Suzuki M, Kawamura Y, et al. (2002) Modulation of oxidative burst of neutrophils by doxycycline in patients with acute myocardial infarction. J Antimicrob Chemother 49: 411-413.
47. Korzyoski T, Kowszyk GZ, Kurylowicz W, eds. (1978) Antibiotics: origin, nature, and properties. American Society for Microbiology pp. 508.
48. Siopi E, Cho AH, Homsi S, Croci N, Plotkine M, et al. (2011) Minocycline restores sAPP alpha levels and reduces the late histopathological consequences of traumatic brain injury in mice. J Neurotrauma 28: 2135-2143.
49. Kaiser JM, Imai H, Haakenson JK, Brucklacher RM, Fox TE, et al. (2012) Nanoliposomal minocycline for ocular drug delivery. Nanomedicine. In press [Epub ahead of print].